Suppr超能文献

退伍军人事务部住院期间阿片类激动剂治疗:一项实用的回顾性队列分析。

Opioid Agonist Therapy During Hospitalization Within the Veterans Health Administration: a Pragmatic Retrospective Cohort Analysis.

机构信息

School of Medicine, MD/PhD Program, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd, Mail Code: L357, Portland, OR, 97239, USA.

School of Public Health, Oregon Health & Science University-Portland State University, Portland, OR, USA.

出版信息

J Gen Intern Med. 2020 Aug;35(8):2365-2374. doi: 10.1007/s11606-020-05815-0. Epub 2020 Apr 14.

Abstract

BACKGROUND

Hospitalization of patients with opioid use disorder (OUD) is increasing, yet little is known about opioid agonist therapy (OAT: methadone and buprenorphine) administration during admission.

OBJECTIVE

Describe and examine patient- and hospital-level characteristics associated with OAT receipt during hospitalization in the Veterans Health Administration (VHA).

PARTICIPANTS

A total of 12,407 unique patients, ≥ 18 years old, with an OUD-related ICD-10 diagnosis within 12 months prior to or during index hospitalization in fiscal year 2017 from 109 VHA hospitals in the continental U.S.

MAIN MEASURE

OAT received during hospitalization.

KEY RESULTS

Few admissions received OAT (n = 1914; 15%) and when provided it was most often for withdrawal management (n = 834; 7%). Among patients not on OAT prior to admission who survived hospitalization (n = 10,969), 2.0% (n = 203) were newly initiated on OAT with linkage to care after hospital discharge. Hospitals varied in the frequency of OAT delivery (range, 0 to 43% of qualified admissions). Patients with pre-admission OAT (adjusted odds ratio [AOR] = 15.30; 95% CI [13.2, 17.7]), acute OUD diagnosis (AOR = 2.3; 95% CI [1.99, 2.66]), and male gender (AOR 1.52; 95% CI [1.16, 2.01]) had increased odds of OAT receipt. Patients who received non-OAT opioids (AOR 0.53; 95% CI [0.46, 0.61]) or surgical procedures (AOR 0.75; 95% CI [0.57, 0.99]) had decreased odds of OAT receipt. Large-sized (AOR = 2.0; 95% CI [1.39, 3.00]) and medium-sized (AOR = 1.9; 95% CI [1.33, 2.70]) hospitals were more likely to provide OAT.

CONCLUSIONS

In a sample of VHA inpatient medical admissions, OAT delivery was infrequent, varied across the health system, and was associated with specific patient and hospital characteristics. Policy and educational interventions should promote hospital-based OAT delivery.

摘要

背景

因阿片类药物使用障碍(OUD)而住院的患者人数不断增加,但人们对在退伍军人事务部(VHA)住院期间接受阿片类激动剂治疗(OAT:美沙酮和丁丙诺啡)的情况知之甚少。

目的

描述并检查与 2017 财年期间美国大陆 109 家 VHA 医院 12 个月内或期间因 OUD 相关 ICD-10 诊断而住院的患者和医院特征相关的 OAT 接受情况。

参与者

共 12407 名年龄≥18 岁的独特患者,在 2017 财年期间因 OUD 相关 ICD-10 诊断而住院,或在住院前 12 个月内有 OUD 相关 ICD-10 诊断。

主要测量指标

住院期间接受的 OAT。

主要结果

很少有入院患者接受 OAT(n=1914;15%),而提供的 OAT 最常用于戒断管理(n=834;7%)。在未入院前接受 OAT 治疗且存活出院的患者(n=10969)中,有 2.0%(n=203)在出院后新开始接受 OAT 治疗并与治疗机构建立联系。各医院提供 OAT 的频率存在差异(范围为 0 至 43%的合格入院患者)。入院前接受 OAT 治疗(调整后的优势比 [AOR],15.30;95%CI [13.2,17.7])、急性 OUD 诊断(AOR,2.3;95%CI [1.99,2.66])和男性(AOR 1.52;95%CI [1.16,2.01])的患者更有可能接受 OAT 治疗。接受非 OAT 类阿片类药物(AOR,0.53;95%CI [0.46,0.61])或手术治疗(AOR,0.75;95%CI [0.57,0.99])的患者接受 OAT 的可能性较低。大型(AOR=2.0;95%CI [1.39,3.00])和中型(AOR=1.9;95%CI [1.33,2.70])医院更有可能提供 OAT。

结论

在 VHA 住院内科入院患者中,OAT 的使用并不常见,在整个医疗体系中存在差异,且与特定的患者和医院特征相关。政策和教育干预措施应促进医院提供 OAT。

相似文献

1
Opioid Agonist Therapy During Hospitalization Within the Veterans Health Administration: a Pragmatic Retrospective Cohort Analysis.
J Gen Intern Med. 2020 Aug;35(8):2365-2374. doi: 10.1007/s11606-020-05815-0. Epub 2020 Apr 14.
2
Polysubstance use and association with opioid use disorder treatment in the US Veterans Health Administration.
Addiction. 2021 Jan;116(1):96-104. doi: 10.1111/add.15116. Epub 2020 Jul 7.
3
Initiating opioid agonist treatment for opioid use disorder nationally in the Veterans Health Administration: Who gets what?
Subst Abus. 2020;41(1):110-120. doi: 10.1080/08897077.2019.1640831. Epub 2019 Aug 12.
4
Predictors of timely opioid agonist treatment initiation among veterans with and without HIV.
Drug Alcohol Depend. 2019 May 1;198:70-75. doi: 10.1016/j.drugalcdep.2019.01.038. Epub 2019 Mar 9.
5
Utilization of buprenorphine and methadone among opioid users who inject drugs.
Subst Abus. 2018 Jan 2;39(1):83-88. doi: 10.1080/08897077.2017.1363844. Epub 2017 Sep 18.
6
Trends in engagement in the cascade of care for opioid use disorder, Vancouver, Canada, 2006-2016.
Drug Alcohol Depend. 2018 Aug 1;189:90-95. doi: 10.1016/j.drugalcdep.2018.04.026. Epub 2018 May 29.
7
Receipt of opioid agonist treatment in the Veterans Health Administration: facility and patient factors.
Drug Alcohol Depend. 2012 May 1;122(3):241-6. doi: 10.1016/j.drugalcdep.2011.10.004. Epub 2011 Nov 23.
8
The cascade of care for opioid use disorder: a retrospective study in British Columbia, Canada.
Addiction. 2020 Aug;115(8):1482-1493. doi: 10.1111/add.14947. Epub 2020 Feb 6.
9
Association of Early Opioid Withdrawal Treatment Strategy and Patient-Directed Discharge Among Hospitalized Patients with Opioid Use Disorder.
J Gen Intern Med. 2023 Aug;38(10):2289-2297. doi: 10.1007/s11606-023-08059-w. Epub 2023 Feb 14.

引用本文的文献

4
6
Toward a Consensus on Strategies to Support Opioid Use Disorder Care Transitions Following Hospitalization: A Modified Delphi Process.
J Gen Intern Med. 2025 Apr;40(5):1048-1058. doi: 10.1007/s11606-024-09108-8. Epub 2024 Oct 22.
9
Barriers and facilitators to implementing treatment for opioid use disorder in community hospitals.
J Subst Use Addict Treat. 2024 Dec;167:209520. doi: 10.1016/j.josat.2024.209520. Epub 2024 Sep 10.
10
Addiction Consult Service and Inpatient Outcomes Among Patients with OUD.
J Gen Intern Med. 2024 Nov;39(15):2961-2969. doi: 10.1007/s11606-024-08837-0. Epub 2024 Aug 13.

本文引用的文献

2
A Call to Action: Hospitalists' Role in Addressing Substance Use Disorder.
J Hosp Med. 2020 Mar;15(3):184-187. doi: 10.12788/jhm.3311.
3
Things We Do for No Reason™: Discontinuing Buprenorphine When Treating Acute Pain.
J Hosp Med. 2019 Oct 1;14(10):633-635. doi: 10.12788/jhm.3265. Epub 2019 Aug 16.
5
U.S. National 90-Day Readmissions After Opioid Overdose Discharge.
Am J Prev Med. 2019 Jun;56(6):875-881. doi: 10.1016/j.amepre.2018.12.003. Epub 2019 Apr 17.
6
Biased labels: An experimental study of language and stigma among individuals in recovery and health professionals.
Subst Use Misuse. 2019;54(8):1376-1384. doi: 10.1080/10826084.2019.1581221. Epub 2019 Apr 4.
7
Predictors of substance use treatment initiation and engagement among adult and adolescent Medicaid recipients.
Subst Abus. 2019;40(3):285-291. doi: 10.1080/08897077.2018.1550467. Epub 2019 Feb 13.
8
Predictors for 30-Day and 90-Day Hospital Readmission Among Patients With Opioid Use Disorder.
J Addict Med. 2019 Jul/Aug;13(4):306-313. doi: 10.1097/ADM.0000000000000499.
9
Role of the Hospital in the 21st Century Opioid Overdose Epidemic: The Addiction Medicine Consult Service.
J Addict Med. 2019 Mar/Apr;13(2):104-112. doi: 10.1097/ADM.0000000000000496.
10
Buprenorphine Deregulation and Mainstreaming Treatment for Opioid Use Disorder: X the X Waiver.
JAMA Psychiatry. 2019 Mar 1;76(3):229-230. doi: 10.1001/jamapsychiatry.2018.3685.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验